The expert advisory group for this health technology assessment (HTA) was established to assess the clinical and economic impact of transcatheter aortic valve implantation (TAVI) for the treatment of patients with severe symptomatic aortic stenosis at low and intermediate surgical risk. The public and/or patient (PPI) representatives were involved in supporting HIQA to fulfil its health technology assessment function. All expert advisory group members provided input into the process (for example, forming the terms of reference, drafting key considerations in the report, interpreting research findings) and they also provide peer review of the project report. The public and/or patient representatives were engaged from June to December 2019. The expert advisory group met twice during this period.
